

# Value drivers for therapies in Fabry disease: findings from a European payer and clinician study

Pedro Borga,<sup>1</sup> Simon Shohet,<sup>1</sup> Sonika Awasthy<sup>2</sup>

*<sup>1</sup>Amicus Therapeutics UK Ltd, Marlow, UK; <sup>2</sup>OPEN Health, London, UK*

These supplementary material slides have been provided by the authors to give readers additional information about the poster.

Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) EU Annual Symposium;  
Barcelona, Spain; 17–20 November 2024

## Supplementary methods

- To generate the lists of unmet needs and value drivers, the project team gathered attributes that are typically known to affect physician and payer choices regarding disease management and adapted to Fabry disease outcomes where relevant (eg renal and cardiac efficacy)
- All questions were answered by each respondent
- Payers were screened to ensure they had experience in advising or decision-making on pricing, access or formulary management for medicines for rare diseases
- Clinicians were screened to ensure they had experience in treating or advising treatment decisions in Fabry disease
- All participants were screened to ensure that they did not have a conflict of interest and that they were compliant with any institutional/employer restrictions on participating in market research
  - Clinicians were selected if they had worked in their roles for more than 3 years and less than 35 years
- European guidelines for market research activities were followed, and an honorarium was paid in line with fair market rates